..."why"????...uhhhhhh, to make money, maybe?..."wasting their time"???...not if their brokers can line enough SUCKERS to buy the hype AND the stock!...
...I'm still trying to find all the "more information" from the trials ORMD did back in 2005-2007!...And Kidron?...isn't that the IDIOT who apparently doesn't know how many international units are in a milligram of insulin? ...oh, yeah, she's REAL "prominent" all right -- prominently STUPID!...just ANOTHER Israeli SCAM company...
...let me count the ways -- oh, here's one, "CNAT"!...
...so Pfizer acquires "Idun" and "idn-6556" in 2005 for "undisclosed" terms...five years later CNAT buys BACK "Idun" and "idn-6556"?...why did Pfizer sell?...I presume it wasn't because of all the "wealth" they were anticipating from future sales of the drug...
...from the 10-Q, say what:
"In July 2010, the Company entered into a $1.0 million promissory note payable to Pfizer Inc. The note bears interest at 7% per annum, which is paid quarterly, and matures on July 29, 2020."
So Pfizer even lent them the money to buy Idun and idn-6556 back???? And I presume a million bucks was roughly the purchase price, which tells you how much Pfizer thought it was worth.
Then CNAT spun off Idun to shaeholders and valued it at a whopping $500,000, which I guess means that "idn-6556" is really roughly worth only $500,000.
But in 2013, Jesus apparently walked on water again and made CNAT worth a 69 MILLION dollar IPO? Can I have an "amen"?
Then look at the phase 2 trial -- "primary outcome measure" is "Pharmacokinetics." SECONDARY outcome is "clinical outcome measure."
Seriously? Funny, I always thought phase 1 was pharmacokinetics, while phase 2 was dosing and initial establishment of "clinical outcome" measures according to dosing.
I saw enough at that point. Pfizer's "loss' was Wall Street's beokers' gain. I can only hope there aren't too many naive enough to buy into whatever hype is coming.
...just happened to stumble over the PR about ACUR "settling" its lawsuit against Sandoz -- lengthy, complicated PR that really boiled down to one sentence:
"...Sandoz is not obligated to pay Acura a royalty if its current formulation of its generic to the AVERSION..."
...it took EIGHT paragraphs to say that?...I wonder how many ACUR executives it takes to change a lightbulb!...HAW!!...
I also like that comment:
"Acura's President and CEO, Bob Jones said, "We are very pleased to have now concluded all our patent infringement suits concerning AVERSION oxycodone..."
Gee, Bob, you're happy you LOST? A little overly sportsmanlike of you, I must say! Especially considering how many millions in shareholder equity you presumably flushed down the toilet trying shakedown Sandoz!
I checked ENMD's website to find the ASCO poster for the ovarian cancer, and I read it but I swear I couldn't find any results anywhere! What was it supposed to be -- an "ad" for their clinical trial or what?
I also looked at the other poster for sarcoma and saw it reported a "clinical benefit rate" was 27%. I don't even know if that's good or bad since I consider "CBR" to be just another "dog and pony show" measurement designed specifically to make results look better than they really are. However, the "secondary objective" of overall survival was NOT reached. So what else is new, right?
Can't think of too many stocks that deserve it more! Now if it can just hurry up and get to where it belongs at ZERO, then I gratefully be able to ignore it again!
...it's on their website...note that you can probably spit farther than you can trust positive results from ANY study done in China...also note that the paper included three VTL employees -- no chance of bias there, huh?...
...oh, yes, several...largest is Millipore and Pharmacell collaboration...the University of Pretoria used to have one of their own design for sale to interested entrepreneurs -- in case you're interested in going into the biotech scam business.
Sentiment: Strong Sell
VTL's "artificial liver"????
Warning signs -- first, publications. Two in 12 YEARS. The first one in 2002 was just a safety study that reported some results from five patients but nothing of relevance to patient outcome. The second was from 2007 -- " Interim Results of Randomized Controlled Trial of ELAD in Acute on Chronic Liver Disease" -- and reported some remarkable results. Problems -- it was done in CHINA (I note sudden flare of large red flashing lights in my peripheral vision) and the authors included THREE Vital Therapies' employees (whoa!...now I'm hearing very loud sirens!).
Second -- presentations. From 2010 -- "Safety and Efficacy of the Extacorporeal Liver Assist Device (ELAD®) in patients with Acute on Chronic Liver Failure" -- "survival data encouraging." Using the word "encouraging" when describing study results usually means it's NOT "encouraging." Interesting conclusions that the authors came to regarding future study design -- enroll patients with fewer complications, enroll patients with lower "model for end-stage liver disease" scores, use "prevention of disease progression" PRIOR to transplant/death as the primary endpoint. In other words, avoid sick patients, avoid patients whose livers are too far gone, and use "progression" rather than survival as an end-point. Why, of course! Why not exclude liver patients entirely and just drag in some perfectly healthy souls off the street -- that should produce GREAT results!
I guess the FDA didn't buy VTL's logic entirely because the presentations from 2012 and 2013 can be came to the same conclusion: "Differences in survival were NOT statistically significant." Is there any reason to believe that a phase 3 study will alter that conclusion? None that I can think of.
How does wall street manage to sell this stuff? It just amazes me that ANYONE with an IQ greater than a grapenut would plunk down even a nickel for this stock!
...just THIRTEEN DOLLARS???...per SHARE???...is that right?...oh, wow!...like yeah, sign me up to buy a few hundred thousand shares -- NOT!!!...and the CEO gets paid HOW MUCH a year?...note for my "to do" list -- take some loser company public and pay myself a LOT of money to make it an even BIGGER loser!...
...I'm soooooooo surprised:
"This prospectus relates to the offer for sale of up to a potential aggregate of 3,897,172 shares of common stock, par value $.0001 per share, of LabStyle Innovations Corp. by the selling stockholders named herein...We will not receive any proceeds from the sales of the above shares of our common stock by the selling shareholders."
...about "national approval and regional reimbursement" in ITALY!...well, whooptedoo!...given Italy is just socialized medicine, that's about as exciting as announcing that the CEO's dog just took a dump in the middle of the street!...can't wait until they announce it's "approved" in Albania!...
...seventy CENTS in only two weeks of trading!...is that some sort of record or what?...what is it they're working on?...rose bengal?...for cancer??...the stuff they use to stain eyeballs when looking for corneal abrasions and such???......for CANCER????...uhhhhh, hold on a second..................ahem!..............................not much longer now!.............................................okay!...here it comes:
HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW , HAW, HAW!!!!!!!!!!!!
...oh, that was a good one!...man, I think I need to go change my depends!!!...rose bengal!...well, what else could you expect from the biotech braintrust in KNOXVILLE, Tennessee?!...HAW!!!...
Sentiment: Strong Sell
...seriously?...you think Allergan or any other pharma couldn't mix a couple of antique generic drugs and get it FDA approved IF they thought it was worth the money?...big pharma recognizes the "bottom line" -- what counts isn't FDA approval, it's third party reimbursement...and if you think medicare and insurance companies are going to fork over $250 for a half gallon of water containing a dime's worth of drugs, better think again...
...who cares...figure 52 million in cash but 32 million in DEBT at end of March!...burning 16 million a quarter means -- on balance -- they're now approaching BROKE -- AGAIN!...which no doubt means it's time to start chaining together some meaningless press releases in order to get ready to print some more stock!...let's see -- shares outstanding 2010 22 million, 2011 22 million, 2012 26 million, 2013 30 million, end of March 33 million...so before December figure another -- what? -- 5 million or so?...
...SCAM this company is? Geez! Six to $32 and back again -- what a racket! Of course, the brokers banking commissions probably laughed themselves silly the entire time! Nevertheless, given the REAL value of this company is LESS than ZERO, there's plenty of downside left. What truly amazes me is how these things ever manage to come public to begin with!